Anti-CLEC2 [AYP2]
Invented at University Of Birmingham
| Catalogue Number | 151913 |
| Applications | FACS IF IP Fn |
| Antigen/Gene or Protein Targets | C-type lectin-like receptor 2, CLEC1b |
| Reactivity | Human |
| Relevance | Patients with rheumatoid arthritis, an inflammatory disease associated with increased microparticle production, have raised plasma levels of microparticles that expressed CLEC-2 but not GPVI. CLEC-2 can be used to monitor platelet-derived microparticles. The observation that microparticles derived from activated platelets retain CLEC-2 but lose GPVI highlights the potential use of measurement of surface expression of platelet receptors to screen for platelet activation in a wide variety of cardiovascular and inflammatory diseases. |
| Host | Mouse |
| Immunogen | A recombinant extracellular fragment of human CLEC-2 (aa 68-229), which is the extracellular domain of the protein |
| Positive Control | Platelets |
| Subclass | IgG1 |
| Molecular Weight (kDa) | 26 |
| Myeloma Used | Sp2/0-Ag14 |
| Recommended Growing Conditions | Hybridomas were cultured at 37ยบ C and 96% relative humidity in air containing 6% CO2. Cells were grown in complete DMEM + Pen/strep + FCS was used at 10%. Cell density: Cells should be kept between 1-2x105 cells/ml and 5x105 cells/ml. |
| Notes |
AYP1 can block the interaction of human CLEC-2 with its endogenous ligand Podoplanin. AYP1 does not cross react with mouse CLEC-2 when tested via FACS. AYP1 does not detect CLEC-2 by western blot. For WB we recommend clone AYP2. |
| Research Area | Cardiovascular, Immunology |
Gitz et al. 2014. Blood. 124(14):2262-70. PMID: 25150298.
CLEC-2 expression is maintained on activated platelets and on platelet microparticles.
Europe PMC ID: 25150298
Gitz et al. 2014. Blood. 124(14):2262-70. PMID: 25150298.
CLEC-2 expression is maintained on activated platelets and on platelet microparticles.